Guardant is another Cathie Wood stock that stands to grow into the huge market for preventative cancer screening. The company uses proprietary blood-based tests and advanced analytics to manage ...

While looking for more home runs, we screened all the companies that Cathie Wood ... develop diagnostic tests for the early detection of various diseases from a single blood test.

The fund family is run by closely watched portfolio manager Cathie Wood. It's best known ... transform thanks to the ...

However, the stock does remain a holding of Cathie Wood's investment management ... approved Guardant Health's Shield blood test for colorectal cancer. If this new, competing diagnostic product ...

While looking for more home runs, we screened all the companies that Cathie Wood ... develop diagnostic tests for the early detection of various diseases from a single blood test.

Cathie Wood is one of Wall Street’s most colorful, controversial and high profile money managers. When she founded Ark Investment Management 10 years ago, she already had more than 30 years in ...

Cathie Wood is a thematic investor focused ... which is developing a blood-based test capable of detecting multiple cancers at early stages; and Base Genomics, which specializes in DNA methylation ...

The loyalty of Cathie Wood’s legion of fans may be finally waning, as the new year bloodbath in speculative technology stocks hands the star money manager a miserable start to 2022. Investors ...

The biggest slide in months for Cathie Wood’s funds is testing the resolve of investors who plowed billions of dollars into one of the hottest firms on Wall Street. All five of Ark Investment ...